Sorafenib, a first-line targeted therapy approved for advanced HCC treatment (since 2008) [365], functions by suppressing EGFR 1–3 and PDGFR-II, acting as an anti-angiogenic agent [366]. The gene discussed is EGFR; the disease is hepatocellular carcinoma.